This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Google Scholar Articles by Gu, Y. Articles by Yao, K. PubMed PubMed Citation Articles by Gu, Y. Articles by Yao, K. Related Collections Male Endocrinology

Multicenter Contraceptive Efficacy Trial of Injectable Testosterone Undecanoate in Chinese Men

National Research Institute for Family Planning (Y.G., X.L.), Beijing 100081, China; Guangzhou Institute for Population and Family Planning (W.W.), Guangzhou 510630, China; Guizhou Institute for Population and Family Planning (M.L.), Guiyang 550004, China; Hebei Research Institute for Family Planning (S.S.), Shijiazhuang 050071, China; Henan Research Institute for Population and Family Planning (L.C., L.B.), Zhengzhou 450002, China; Family Planning Research Institute (C.X.), Tongji Medical College, Wuhan 430030, China; Jiangsu Family Planning Research Institute (X.W.), Nanjing 210036, China; Sichuan Family Planning Research Institute (X.L.), Chengdu 610041, China; Yunnan Family Planning Research Institute (L.P.), Kunming 650021, China; and Zhejiang Institute of Planned Parenthood (K.Y.), Hangzhou 310012, China

Address all correspondence and requests for reprints to: Yiqun Gu, M.D., Professor, Department of Male Clinic Research, National Research Institute for Family Planning, 12 Da Hui Si Road, Haidian District, Beijing 100081, China. E-mail: ygu90{at}yahoo.cn.

Context: Hormonal male contraceptive regimens effectively and reversibly suppress sperm production, but there are few large-scale efficacy studies.

Objective: The safety, contraceptive efficacy, reversibility, and feasibility of injectable testosterone undecanoate (TU) in tea seed oil as a hormonal male contraceptive was assessed.

Design: This was a multicenter, phase III, contraceptive efficacy clinical trial.

Participants: A total of 1045 healthy fertile Chinese men were recruited throughout China into the study.

Intervention(s): Injections of 500 mg TU were administered monthly for 30 months. A definition of severe oligozoospermia (1 x 10⁶/ml) was used as a criterion of spermatogenic suppression and as the threshold for entering the contraceptive efficacy phase.

Main Outcome Measure(s): The primary outcome was pregnancy rate in the partner. Other outcomes include: semen parameters, testis volumes, reproductive hormone levels, and safety laboratory tests.

Results: Forty-three participants (4.8%) did not achieve azoospermia or severe oligozoospermia within the 6-month suppression phase. A total of 855 participants entered into the efficacy phase, and 733 participants completed monthly TU treatment and follow-up. There were nine pregnancies in 1554.1 person-years of exposure in the 24-month efficacy phase for a cumulative contraceptive failure rate of 1.1 per 100 men. The combined method failure rate was 6.1%, comprising 4.8% with inadequate suppression and 1.3% with postsuppression sperm rebound. No serious adverse events were reported. Spermatogenesis returned to the normal fertile reference range in all but two participants.

Conclusions: Monthly injection of 500 mg TU provides safe, effective, reversible, and reliable contraception in a high proportion of healthy fertile Chinese men.

This article has been cited by other articles:

				E. Nieschlag Male Hormonal Contraception: Love's Labour's Lost? J. Clin. Endocrinol. Metab., June 1, 2009; 94(6): 1890 - 1892. [Full Text] [PDF]